Pear Therapeutics, Inc.
PEAR · NASDAQ
12/31/2022 | 9/30/2022 | 6/30/2022 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | $163,674 | $283,472 | $227,030 | $696,153 |
| - Cash | $48,301 | $59,685 | $60,185 | $89,434 |
| + Debt | $37,607 | $38,063 | $38,392 | $38,625 |
| Enterprise Value | $152,980 | $261,850 | $205,237 | $645,344 |
| Revenue | $2,565 | $4,083 | $3,297 | $2,749 |
| % Growth | -37.2% | 23.8% | 19.9% | – |
| Gross Profit | $820 | $1,528 | $896 | $1,268 |
| % Margin | 32% | 37.4% | 27.2% | 46.1% |
| EBITDA | -$32,302 | -$21,709 | -$70,045 | -$45,343 |
| % Margin | -1,259.3% | -531.7% | -2,124.5% | -1,649.4% |
| Net Income | $28,827 | -$34,817 | $43,744 | -$12,977 |
| % Margin | 1,123.9% | -852.7% | 1,326.8% | -472.1% |
| EPS Diluted | 0.21 | -0.25 | 0.3 | -0.094 |
| % Growth | 184% | -183.3% | 418.8% | – |
| Operating Cash Flow | -$24,280 | -$23,270 | -$29,637 | -$36,708 |
| Capital Expenditures | -$1,070 | -$580 | -$1,319 | -$501 |
| Free Cash Flow | -$25,350 | -$23,850 | -$30,956 | -$37,209 |